A recruitment drive to fill up to 100 new jobs has been launched at a Northumberland pharma firm, following on from recent £6.3m expansion plans.
Drug development and manufacturing accelerator Quotient Sciences expanded into the North East in 2021 when it acquired the Alnwick base from Arcinova in an undisclosed deal. The company, which provides drug substance, drug product and bioanalysis services to more than 200 pharma and biotech customers worldwide, launched multimillion-pound investment plans to expand its manufacturing operations at the site, which created an additional 80 to 100 new scientific and technical jobs at the facility.
The expansion saw Quotient Sciences tap into unused space, repurposing a 1,500sqm testing facility which had been left unused since 2016, incorporating additional equipment and technologies, significantly expanding the number of new molecules developed each year. Now employing more than 200 people across scientific disciplines including process chemistry, radiosynthesis, analytical science, bioanalysis and formulation development, the firm is creating more roles.
